Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications.

Saved in:
Bibliographic Details
Title: Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications.
Authors: Rasmussen ASB; Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100, Copenhagen, Denmark., Rank CU; Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Christensen IJ; Molecular Unit, Department of Pathology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark., Weimann A; Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100, Copenhagen, Denmark., Hansen K; Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100, Copenhagen, Denmark., Thastrup M; Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100, Copenhagen, Denmark., Yang T; Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Lund TM; Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Wik HS; Department of Haematology, Oslo University Hospital Rikshospitalet, Oslo, Norway., Vogt H; Department of Biomedical and Clinical Science, Linköping University, Linköping, Sweden.; Crown Princess Victoria Children's Hospital, Region Östergötland, Linköping, Sweden., Norén-Nyström U; Department of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden., Vaitkeviciene G; Clinic of Children's Diseases, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania.; Center for Pediatric Oncology and Hematology, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania., Albertsen BK; Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Wehner PS; Department of Pediatric Hematology and Oncology, H. C. Andersen Children's Hospital, Odense University Hospital, Odense, Denmark., Als-Nielsen B; Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100, Copenhagen, Denmark., Andersen CL; Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Research Unit for General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark., Dalhoff K; Department of Clinical Pharmacology, Copenhagen University Hospital, Bispebjerg, Copenhagen, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Schmiegelow K; Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100, Copenhagen, Denmark. Kjeld.Schmiegelow@regionh.dk.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Kjeld.Schmiegelow@regionh.dk.
Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2026 Jun 19; Vol. 96 (1). Date of Electronic Publication: 2026 Jun 19.
Publication Type: Journal Article; Multicenter Study
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1432-0843
DOI:10.1007/s00280-026-04914-9